Quantitative biochemical markers of DNA hyperploidy as end-point indicators in chemical risk assessment and chemoprevention studies.
Authors
Hurst RE; Rhodes SW; Petrone RL; Bas RA; Hemstreet GP; Detrisac CL; Thomas C; Moon RC; Kelloff GJ
Source
Biol Monit 1991 Jan; 1(1):5-15
Link
NIOSHTIC No.
00232617
Abstract
The usefulness of quantitative fluorescence image analysis (QFIA) as a biological monitoring tool to measure DNA content in bladder wash cells taken from rats treated with N-butyl-N-(4- hydroxybutyl)nitrosamine (3817116) (OHBBN) was investigated. OHBBN was administered at 100mg twice a week for 8 weeks to 143 Fischer- 344-rats. Of these 143 animals, 36 also received 4- hydroxyphenylretinamide (4-HPR). Animals were sacrificed 6 months after the final dose. There was a small shift toward less invasive tumors in the 4-HPR treated animals, but large differences were noted in the cytological characteristics of the cells, reflecting treatment with carcinogen and retinoid. The mean DNA content in the cells classified as nonnormal was shifted toward more normal values when the rats had also received 4-HPR treatment. The mean DNA content shifted from 10.9C to 5.9C in those cells which were visually suspicious, with 2C being a normal cellular DNA content. The shift from a mean DNA content of 4.4C to 3.7C was noted in visually atypical cells. The authors conclude that there are very distinct differences in the ploidy and cytologic characteristics of the cells detected by acridine-orange fluorescence which can be ascribed to an effect of the retinoid in normalizing the cells. This information may point to the development of more accurate and sensitive markers for monitoring the effects of carcinogens and chemopreventive agents.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.